Literature DB >> 9860226

German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2.

F Raue1.   

Abstract

INTRODUCTION: A national registry for medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia type 2 (MEN2) was set up to evaluate epidemiological, clinical and prognostic factors of the sporadic and hereditary forms of MTC. PATIENTS AND METHODS: Coded data from 1217 patients with MTC from 57 participating centers in Germany were registered and statistically analyzed. The series included 515 (42%) males (mean age 43.1+/-16.1 years) and 702 (58%) females (mean age 44.4+/-17.6 years), with a mean follow-up of 5.2 years; 865 (71%) exhibited the sporadic form and 352 (29%) the familial form (244 MEN2a, 32 MEN2b, 76 FMTC). The mean age at diagnosis was 49 years for sporadic and 30 years for the familial form.
RESULTS: Of the patients, 17% presented at stage I, according to the UICC, and 30%, 45%, and 8% presented at stages II, III, and IV, respectively. There were 12% of patients who died of the disease. The overall adjusted survival rate was 87% at 5 years, and 76% at 10 years. In a univariate analysis, the stage of disease at diagnosis, age, gender, and form were relevant prognostic factors. In a multivariate proportional-hazards analysis, the difference between patients with sporadic and familial disease disappeared.
CONCLUSION: As the tumor stage at presentation is the major prognostic factor, early diagnosis and surgical intervention before cervical lymph node metastases appear is necessary to improve survival especially in sporadic cases.

Entities:  

Mesh:

Year:  1998        PMID: 9860226     DOI: 10.1007/s004230050143

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  13 in total

1.  [Hereditary neuroendrocrine tumors. Multiple endocrine neoplasia type 1 and 2].

Authors:  A Rinke; S R Galan; V Fendrich; P H Kann; D K Bartsch; T M Gress
Journal:  Internist (Berl)       Date:  2012-04       Impact factor: 0.743

Review 2.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.

Authors:  Steven G Waguespack; Thereasa A Rich; Nancy D Perrier; Camilo Jimenez; Gilbert J Cote
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

Review 3.  Update multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Karin Frank-Raue
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

4.  [Medullary thyroid carcinoma].

Authors:  V Tiedje; S Ting; H Dralle; K W Schmid; D Führer
Journal:  Internist (Berl)       Date:  2015-09       Impact factor: 0.743

5.  Skip metastases in medullary thyroid carcinoma: a single-center experience.

Authors:  Marcos R Tavares; Pedro Michaluart; Fabio Montenegro; Sergio Arap; Maria Sodre; Flavio Takeda; Lenine Brandao; Sergio Toledo; Alberto Ferraz
Journal:  Surg Today       Date:  2008-05-31       Impact factor: 2.549

6.  Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.

Authors:  Sara Milićević; Damijan Bergant; Tina Žagar; Barbara Perić
Journal:  Croat Med J       Date:  2021-04-30       Impact factor: 1.351

7.  RET mutations in a large indian family with medullary thyroid carcinoma.

Authors:  D M Mahesh; Arun G Nehru; M S Seshadri; Nihal Thomas; Aravindan Nair; Rekha Pai; Simon Rajaratnam
Journal:  Indian J Endocrinol Metab       Date:  2014-07

8.  Recurrent spinal metastasis of a sporadic medullary carcinoma of the thyroid after radiation therapy: a case report and review of the literature.

Authors:  Christopher Munoz-Bendix; Antonio Santacroce; Kristin Gierga; Frank W Floeth; Hans-Jakob Steiger; Marco Antonio Penalonzo; Sven Oliver Eicker
Journal:  Clin Case Rep       Date:  2015-11-09

9.  Thyroid: Medullary Carcinoma.

Authors:  Yash R Somnay; David Schneider; Haggi Mazeh
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2013-04

10.  Hereditary medullary thyroid carcinoma syndromes: experience from western India.

Authors:  Chakra Diwaker; Vijaya Sarathi; Sanjeet Kumar Jaiswal; Ravikumar Shah; Anuja Deshmukh; Anand Ebin Thomas; Gagan Prakash; Gaurav Malhotra; Virendra Patil; Anurag Lila; Nalini Shah; Tushar Bandgar
Journal:  Fam Cancer       Date:  2021-01-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.